Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same author

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same author

Evidence for multiple past introgressions among chimpanzee subspecies during warming periods.

Communications biology·2026
Same author

Macroevolutionary patterns of endocast lateralization in catarrhines and fossil hominins.

Brain, behavior and evolution·2026
Same author

Replay: Refining the Hepatic Risk Interpretation in APOB Loss-Of-Function.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Traditional cardiovascular risk factors and their association with atherosclerotic cardiovascular disease in homozygous familial hypercholesterolemia: A cross-sectional analysis from the HICC registry.

Atherosclerosis·2026
Same journal

Correction: Diagnostic accuracy and clinical impact of internist-performed point-of-care ultrasound in atrial fibrillation: a multicenter study.

Internal and emergency medicine·2026
Same journal

Managing emergency department overcrowding: analysis through a dynamic simulation model of the impact of organizational variables on emergency department processes.

Internal and emergency medicine·2026
Same journal

Gunshot-induced carotid artery injury: exploring other determined aetiologies of stroke.

Internal and emergency medicine·2026
Same journal

Machine learning phenotypes and heterogeneous albumin effects in cirrhotic AKI: a causal inference study.

Internal and emergency medicine·2026
Same journal

Factors affecting exercise performance at the 6-min walk test in long-COVID: a multicenter study from Italy.

Internal and emergency medicine·2026
Same journal

Does the term "non-compliant" bias physician perceptions? a preliminary inquiry into a single internal medicine residency training program.

Internal and emergency medicine·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Targeting triglycerides for cardiovascular risk reduction.

Carlo Maiorca1,2, Daniele Tramontano3, Alessia Di Costanzo3

  • 1Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. carlo.maiorca@uniroma1.it.

Internal and Emergency Medicine
|May 18, 2026
PubMed
Summary
This summary is machine-generated.

Hypertriglyceridemia (HTG) and triglyceride-rich lipoproteins (TRLs) contribute to cardiovascular risk. Therapies targeting TRL metabolism, like icosapent ethyl, show promise in reducing residual risk in high-risk patients.

Keywords:
Hypertriglyceridemia (HTG)Residual cardiovascular riskTG-lowering therapiesTriglyceride-rich lipoproteins (TRLs)

Related Experiment Videos

Last Updated: May 20, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Area of Science:

  • Cardiology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Residual cardiovascular risk persists despite optimal control of LDL-C, blood pressure, and glycaemia.
  • Hypertriglyceridemia (HTG) and triglyceride-rich lipoproteins (TRLs) are increasingly recognized contributors to atherogenesis and atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

  • To review current knowledge of TRL metabolism and its role in ASCVD.
  • To examine therapeutic strategies for lowering TRL burden and addressing residual cardiovascular risk.

Main Methods:

  • Narrative review of mechanistic studies, observational cohorts, and Mendelian-randomization analyses.
  • Critical examination of traditional and emerging therapeutic strategies targeting TRLs.

Main Results:

  • TRLs exhibit pro-inflammatory and pro-thrombotic properties, contributing to plaque initiation and progression.
  • Conventional therapies (fibrates, omega-3s) show modest, inconsistent benefits.
  • Icosapent ethyl demonstrated significant cardiovascular event reduction.
  • Novel agents (evinacumab, anti-apoC-III ASOs) markedly decrease triglycerides and remnant cholesterol, pending outcome data.

Conclusions:

  • Targeting TRL metabolism is a promising strategy for reducing residual cardiovascular risk.
  • Icosapent ethyl is the only TRL-targeted therapy with proven cardiovascular outcome benefits.
  • Emerging therapies show potential for significant triglyceride and remnant cholesterol reduction.